Oncology/Cancer Drugs Market By Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), and Hormonal Therapy), By Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Other Cancers): Opportunity Analysis and Industry Forecast, 2021–2030
The global oncology/cancer drugs market was valued at $135,494.17 million in 2020, and is projected to reach $274,400.63 million by 2030, registering a CAGR of 7.5% from 2021 to 2030.
Cancer is the uncontrolled growth of abnormal cells in the body. Cancer develops when the body’s normal control mechanism stops working. Old cells do not die and instead grow out of control, forming new, abnormal cells. The treatment of cancer in patients requires the use of different drugs like hormonal therapy, immunotherapy, targeted therapy, and chemotherapy.
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types. Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness, early screening of the cancer and availability of cancer drugs are expected to boost the market growth.
However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.
The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.
Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). The major companies profiled in the report include AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Global Services, LLC,), Merck & Co., Inc., Novartis AG, and Pfizer Inc.
KEY BENEFITS FOR STAKEHOLDERS - This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the oncology/cancer drugs market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
BY DRUG CLASS TYPE • Chemotherapy
• Targeted Therapy
• Immunotherapy (Biologic Therapy)
• Hormonal Therapy
BY INDICATION • Lung Cancer
• Stomach Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Liver Cancer
• Esophagus Cancer
• Cervical Cancer
• Kidney Cancer
• Bladder Cancer
• Other Cancers
By REGION • North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
KEY MARKET PLAYERS • AbbVie Inc.
• Amgen
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson (Janssen Global Services, LLC,)
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
Our reports have been used by over 10K customers, including:
288 pages •
By The Business Research Company
• Jul 2022
Community Oncology Services Global Market Opportunities And Strategies To 2031: COVID-19 Growth And Change provides the strategists; marketers and senior management with the critical information they need to assess the global community oncology services market as it emerges from the COVID 19 shut down. Description: Where...
The Global Interventional Oncology Market size is expected to reach $2.9 billion by 2028, rising at a market growth of 6.2% CAGR during the forecast period. Interventional oncology (IO) is an emerging subspecialty that emphasizes on using image-guided processes (diagnostics/surgeries) to improve cancer therapy. Along with surgery, medication,...
The global radiation oncology market reached a value of US$ 6.97 Billion in 2021. Looking forward, the analyst expects the market to reach a value of US$ 10.88 Billion by 2027, exhibiting a CAGR of 7.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect...
304 pages •
By The Business Research Company
• Jul 2022
Immuno-Oncology Drugs Global Market Opportunities And Strategies To 2031 provides the strategists; marketers and senior management with the critical information they need to assess the global immuno-oncology drugs market as it emerges from the COVID 19 shut down. Description: Where is the largest and fastest growing...
279 pages •
By The Business Research Company
• Jul 2022
Interventional Oncology Devices Global Market Opportunities And Strategies To 2031 provides the strategists; marketers and senior management with the critical information they need to assess the global interventional oncology devices market as it emerges from the COVID-19 shut down. Description: Where is the largest...
915 pages •
By Global Industry Analysts
• Jul 2022
Abstract: What`s New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass...
352 pages •
By Global Industry Analysts
• Jul 2022
Abstract: What`s New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass...
Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028 Report Highlights: • Global Orphan Designated Market Opportunity > USD 170 Billion by 2028 • Global & Regional Market Size 2022 Till 2028 • Market Size By Orphan Designated Cancer Type 2022 Till 2028 • Top 50 Orphan Designated...
The Global Oncology Information Systems Market size is expected to reach $3.4 billion by 2028, rising at a market growth of 7.4% CAGR during the forecast period. The Oncology Information System assists healthcare facilities like hospitals, clinics, and research labs not only in managing and optimizing cancer care solutions, but also...
Oligodendroglioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma – Drugs In Development, 2022, provides an overview of the Oligodendroglioma (Oncology) pipeline...
Cancer
Targeted Therapy
Oncology
Therapy
Drug Development
World
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.